Company Infant Bacterial Therapeutics AB

IBT B

SE0008015259

Pharmaceuticals

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Group companies

Sector

Sector Specialty & Advanced Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 16:06:42 03/05/2024 BST			5-day change	1st Jan Change
88.4 ^SEK	-0.45%		+0.68%	-1.78%

02-08	Infant Bacterial Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI
02-08	Infant Bacterial Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Infant Bacterial Therapeutics AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company develops drugs that meet the needs of the premature infant. The Companyâs focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.

Number of employees: 8

Managers	Title	Age	Since
Staffan Strömberg CEO	Chief Executive Officer	57	31/12/12
Maria Ekdahl DFI	Director of Finance/CFO	51	18/09/22
Erik Anders Kronström COO	Chief Operating Officer	57	19/10/14
Jonas Rastad CTO	Chief Tech/Sci/R&D Officer	74	-
Agneta Heierson PRN	Corporate Officer/Principal	-	-
Leif Gallo LAW	General Counsel	65	-
Michael Owens AUD	Comptroller/Controller/Auditor	68	03/12/15

Members of the board	Title	Age	Since
Margareta Hagman BRD	Director/Board Member	58	23/09/15
Peter Michael Rothschild CHM	Chairman	74	31/12/10
Anthon Jahreskog BRD	Director/Board Member	44	03/05/17
Kristina Sjöblom Nygren BRD	Director/Board Member	63	14/05/18
Eva Idén BRD	Director/Board Member	58	03/05/17

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	10	453,283	0	0	88.04 %
Stock B	1	13,018,137	11,860,512 ( 91.11 %)	0

Name	Equities	%	Valuation
Fjärde AP-fonden 10.32 %	1,344,000	10.32 %	10 M kr
Annwall & Rothschild Investments AB 5.541 %	721,351	5.541 %	5 M kr
Keel Capital AB 5.116 %	666,053	5.116 %	5 M kr
AMF Fonder AB 4.624 %	601,902	4.624 %	5 M kr
Tredje AP-fonden 4.624 %	601,894	4.624 %	5 M kr
Swedbank Robur Fonder AB 4.148 %	540,000	4.148 %	4 M kr
Unionen 4.087 %	532,023	4.087 %	4 M kr
SEB Investment Management AB 3.223 %	419,515	3.223 %	3 M kr
Ålandsbanken Fondbolag AB (Sweden) 3.037 %	395,345	3.037 %	3 M kr
David Dangoor 2.825 %	367,705	2.825 %	3 M kr

Name	Equities	%	Valuation
Annwall & Rothschild Investments AB 100.00 %	453,283	100.00 %	3 M kr

Infant Bacterial Therapeutics AB

Bryggargatan 10

111 21, Stockholm

+46 7 62 19 37 38

http://www.ibtherapeutics.com

address Infant Bacterial Therapeutics AB(IBT B)

Name	Category and Sector
INFANT BACTERIAL THERAPEUTICS AB	Pharmaceuticals: Major

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
INFANT BACTERIAL THERAPEUTICS AB	-1.78%	110M
MERCK KGAA	+5.48%	71.19B
KYOWA KIRIN CO. LTD.	+12.55%	9.3B
SK BIOPHARMACEUTICALS CO., LTD.	-13.75%	5.01B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+42.38%	4.47B
YUHAN CORPORATION	+4.51%	3.96B
BETTA PHARMACEUTICALS CO., LTD.	-19.05%	2.41B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-28.72%	2.23B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+11.13%	2.02B
SUPERNUS PHARMACEUTICALS, INC.	+6.53%	1.69B

Specialty & Advanced Pharmaceuticals